President & Chief Executive Officer (CEO)
Jonas has worked over 25 years in the Life Science sector. He is an assistant professor in pharmacology at Uppsala University, he has a B.Sci. in Chemistry from University of Stockholm, and a Ph.D. in Experimental Neurology from Uppsala University, post-doctoral studies at University of Southern California, School of Pharmacy in LA. He has also received education in strategic planning and business management. Jonas has previously held executive roles in biotech companies in Sweden, US and Switzerland. Most recently, he served as CEO for the Swiss biotech BOWS Pharmaceuticals SA, and prior held senior and executive positions in Pharmacia, Biovitrum, Sequenom and Invitrogen. Jonas has worked as CEO in the group since 2010. Between 2015 and 2017 he was consultant CEO. He was employed as president and CEO for the group since 2017.
Other Assignments: Board director in CombiGene AB, EffRx Pharmaceuticals SA and World 5 Ventures, as well as in Pergamum AB and Pergasus AB, which are subsidiaries of Promore Pharma AB.
Share Holding in Promore Pharma: 51,666 shares.
Chief Financial Officer (CFO)
Erik has more than 25 years of senior financial management experience from small and medium-sized companies. He is a senior economist with vast experience in the field of finance and economy. Most recently, he was the Senior Business Controller and the Financial Director for Coop Online AB. He has also served as CFO at SentoClone AB, a biotech company within the field of T-cells based cancer therapy. Erik joined the company in 2020. Erik is also CFO at Emplicure and Quiapeg Pharmaceuticals Holding.
Share Holding in Promore Pharma: 82,982 shares.
Chief Scientific Officer (CSO)
Margit has over 15 years of experience in pharmaceutical research and development. She has had assignments at companies such as AstraZeneca, Arexis, and Swedish Orphan Biovitrum. Margit holds a professorship in Molecular Medicine at University of Gothenburg, Sweden. She has a Ph.D. in Molecular and Cellular Biology from the University of Gothenburg. Margit joined the company in 2007 and has since then been responsible for regulatory affairs strategy and clinical development.
Other Assignments: Margit is a director of the board in Sixera AB, she is CEO of to IP holding companies ScandiCure AB and Alexera AB and she is CEO and chairman of her own consultancy practice Arexela AB, an intellectual property holding company.
Share Holding in Promore Pharma: No current holding.
Holdings as of December 1, 2021.